Clindamycin

C. diff Risk

High

Oral Bioavailability

Excellent

Approximate Cost

Dosing

Adult

Usual indications
600 mg IV q8h (MSH Autosub dose)

Necrotizing SSTI or toxic shock syndrome
900mg IV q8h

Oral Dosing
300-450mg PO q6h

Renal

No adjustment required

General Information

Common Usage

Anaerobic infections above the diaphragm, especially dental infection.

Gram positive skin and soft tissue infections including necrotizing fasciitis as an adjunctive agent to a beta lactam for reducing toxin production.

Skin & soft tissue infections involving susceptible MRSA.

Susceptible infections and surgical prophylaxis in setting of IgE mediated beta-lactam allergy.

For decreasing toxin production in toxic shock syndrome.

Drug Monitoring

None specific. Monitor for diarrhea.

Major Interactions

Muscle relaxants, e.g., atracurium, baclofen, diazepam.

St. Johns Wort

Pharmacology

Antimicrobial class: Lincosamide

Pregnancy category: B

Average serum half life: 2.4 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor